TY - JOUR
T1 - Genotypic and phenotypic characterization of Noonan syndrome
T2 - New data and review of the literature
AU - Jongmans, Marjolijn
AU - Sistermans, Erik A.
AU - Rikken, Alwin
AU - Nillesen, Willy M.
AU - Tamminga, Rienk
AU - Patton, Michael
AU - Maier, Esther M.
AU - Tartaglia, Marco
AU - Noordam, Kees
AU - Van Der Burgt, Ineke
PY - 2005/4/15
Y1 - 2005/4/15
N2 - Noonan syndrome (NS) is an autosomal dominant disorder, characterized by short stature, minor facial anomalies, and congenital heart defects. In approximately 50% of cases the condition is caused by missense mutations in the PTPN11 gene on chromosome 12, resulting in a gain of function of the protein SHP-2. In this study, PTPN11 mutation analysis was performed in 170 NS patients. In 76 (45%) of them a mutation was identified. We report on the distribution of these mutations, as well as on genotype-phenotype relationships. The benefit of the NS scoring system developed by van der Burgt et al. [(1994); Am J Med Genet 53:187-191] is shown, among physicians who consequently based their diagnosis on the NS scoring system the percentage mutation positive subjects was 54%, whereas this percentage was only 39% among physicians who made less use of the scoring system. In two patients with some uncommon manifestations mutations were found in the C-SH2 domain, a region in which defects are not often identified in NS. A trend was observed in patients carrying the 922A → G change (Asn308Asp) receiving normal education. In one patient with NS and mild juvenile myelomonocytic leukemia (JMML) the mutation 218C → T (Thr73Ile) was found. This confirms previous findings indicating that individuals with NS with specific mutations in PTPN11 are at risk of developing JMML.
AB - Noonan syndrome (NS) is an autosomal dominant disorder, characterized by short stature, minor facial anomalies, and congenital heart defects. In approximately 50% of cases the condition is caused by missense mutations in the PTPN11 gene on chromosome 12, resulting in a gain of function of the protein SHP-2. In this study, PTPN11 mutation analysis was performed in 170 NS patients. In 76 (45%) of them a mutation was identified. We report on the distribution of these mutations, as well as on genotype-phenotype relationships. The benefit of the NS scoring system developed by van der Burgt et al. [(1994); Am J Med Genet 53:187-191] is shown, among physicians who consequently based their diagnosis on the NS scoring system the percentage mutation positive subjects was 54%, whereas this percentage was only 39% among physicians who made less use of the scoring system. In two patients with some uncommon manifestations mutations were found in the C-SH2 domain, a region in which defects are not often identified in NS. A trend was observed in patients carrying the 922A → G change (Asn308Asp) receiving normal education. In one patient with NS and mild juvenile myelomonocytic leukemia (JMML) the mutation 218C → T (Thr73Ile) was found. This confirms previous findings indicating that individuals with NS with specific mutations in PTPN11 are at risk of developing JMML.
KW - C-SH2 domain
KW - Juvenile myelomonocytic leukemia (JMML)
KW - Noonan syndrome
KW - PTPN11
UR - http://www.scopus.com/inward/record.url?scp=20144389353&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.30598
DO - 10.1002/ajmg.a.30598
M3 - Review article
C2 - 15723289
AN - SCOPUS:20144389353
SN - 1552-4825
VL - 134 A
SP - 165
EP - 170
JO - American Journal of Medical Genetics
JF - American Journal of Medical Genetics
IS - 2
ER -